Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | BIRC7 | Q96CA5 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28809333 | 0.82 | ATM (0.54) | ATMDPP4ITGB3ITGA2B | |
| SCHEMBL1504386 | 0.79 | DPP4 (0.53) | DPP4PIK3CDFAP | |
| SCHEMBL15323564 | 0.74 | DPP4 (0.48) | DPP4FAP | |
| SCHEMBL3032665 | 0.74 | ATM (0.53) | ATMDPP4PIK3CDFAP | |
| SCHEMBL3032663 | 0.74 | ATM (0.53) | ATMDPP4PIK3CDFAP | |
| SCHEMBL18720347 | 0.74 | ATM (0.53) | ATMDPP4PIK3CDFAP | |
| SCHEMBL30317617 | 0.71 | L3MBTL1 (0.41) | — | |
| SCHEMBL24943291 | 0.70 | GNAI3 (0.40) | — | |
| SCHEMBL15177041 | 0.70 | GNAI3 (0.40) | — | |
| SCHEMBL34461083 | 0.69 | ACE (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 988 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743576-A1 | RNA-EDITING OLIGONUCLEOTIDES AND USES THEREOF | Korro Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4744669-A2 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026101913-A1 | SIRNAS TARGETING COMPLEMENT FACTOR H-RELATED (CFHR) GENE TRANSCRIPTS AND METHODS OF USE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4729120-A2 | METHODS AND COMPOSITIONS FOR TREATING A BLEEDING EVENT IN A SUBJECT HAVING HEMOPHILIA | Genzyme Corporation (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260103715-A1 | POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12594253-B2 | HIV inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNGDER WISSENSCHAFTEN E.V. (DE) | 2026-04-07 | — | — | US | disclosed |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12577564-B2 | Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260071212-A1 | GalNAc conjugated oligonucleotides for RNA editing | KORRO BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12569511-B2 | Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20130317081-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2013-11-28 | — | — | US | disclosed |
| US-20130289094-A1 | Compositions and Methods for Inhibition of PCSK9 Genes | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2013163430-A2 | SERPINC1 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20130281511-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | BANK OF AMERICA, N.A. | 2013-10-24 | — | — | US | disclosed |
| WO-2013155204-A2 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-10-17 | — | — | WO | disclosed |
| EP-2633046-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF PCSK9 GENES | Alnylam Pharmaceuticals, Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130184324-A1 | Dual Targeting siRNA Agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2012177784-A2 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSTIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012058693-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF PCSK9 GENES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2011038031-A1 | DUAL TARGETING SIRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577564-B2 | Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof | SREBF1, SREBF2, ATF4 | SIRT6 2337/4885SIRT1 2111/4885OGA 629/4885 |
| US-12569511-B2 | Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof | PNPLA2, PLAAT3, RNGTT | SIRT6 2430/4885SIRT1 3053/4885OGA 238/4885 |
| US-12594253-B2 | HIV inhibitors | TRMT1, NSUN2, NSUN3 | SIRT6 3442/4885SIRT1 3657/4885OGA 816/4885 |
| US-20260103715-A1 | POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF | PDCD1LG2, CD274, PDCD1 | SIRT6 3682/4885SIRT1 3838/4885OGA 2028/4885 |
| US-20260071212-A1 | GalNAc conjugated oligonucleotides for RNA editing | NSUN3, ADAR, TRMT1L | SIRT6 3271/4885SIRT1 3347/4885OGA 62/4885 |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | AGT, AGTR2, AGTR1 | SIRT6 4314/4885SIRT1 4469/4885OGA 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.